Summary
Chris Kay is a human geneticist and research fellow with 11 years of experience probing molecular causes of inherited neurological disorders, notably Huntington disease and other repeat expansion conditions. He leads and designs genetic studies at the Centre for Brain Research, focusing on somatic CAG repeat expansion and therapeutic gene silencing strategies that have informed patent filings and industry collaborations. A 2023 HDSA Berman-Topper Fellow and 2025 Huntington Disease Career Advancement Grant recipient, he has published widely—including first-author work—on haplotypes, therapeutic targets, and clinical risk estimates now cited in ACMG guidelines. His background uniquely blends academic discovery, technology transfer, and IP prosecution in life sciences, giving him fluency in both translational research and commercialization. Trained under Dr. Michael Hayden for his PhD, Chris has repeatedly translated mechanistic insight into practical guidance for therapies and genetic counselling. Based in Auckland, he continues to bridge deep molecular expertise with real-world impact on HD treatment development.
11 years of coding experience
15 years of employment as a software developer
Doctor of Philosophy (PhD), Medical Genetics, Doctor of Philosophy (PhD), Medical Genetics at The University of British Columbia
BSc, Molecular Biology, BSc, Molecular Biology at University of West Florida
Technical Core, Technical Core at Harvey Mudd College
English, French